Introduction
Taxanes (paclitaxel and docetaxel) are cytotoxic anticancer agents used to treat various types of cancers. In patients with advanced-stage cancer, therapeutic options regarding treatment with anticancer drugs are limited. [1] [2] [3] Although various anticancer drugs, including taxanes, are known to be effective for various types of cancers, 4-8 a few options for anticancer drug treatment are available for patients with advanced cancer. Hence, it is important to try all the available anticancer drugs with these patients.
Previously, several retrospective studies have reported an incomplete crossresistance between paclitaxel and docetaxel in various cancer types. [9] [10] [11] [12] These studies reported the moderate efficacy of the second taxane treatment in some patients who became refractory to the first taxane treatment. Based on these findings, patients refractory to the first taxane treatment have often been treated with the second taxane
Patients and methods Patients
We retrospectively reviewed the medical records of patients between 2005 and 2017 (n=2,233) with a histopathological diagnosis of squamous cell carcinoma of the head and neck or esophagus or adenocarcinoma of the stomach or breast at the Department of Medical Oncology, Tohoku University Hospital (Sendai, Japan). In this study, we enrolled all patients successively treated with paclitaxel and docetaxel (either paclitaxel-docetaxel or docetaxel-paclitaxel; n=31). In contrast, we excluded patients treated with anticancer drugs other than the two taxanes.
Chemotherapy regimens
Patients with head and neck cancer and esophageal cancer received recurrent docetaxel (70 mg/m 2 ) infusions every 3 weeks or recurrent paclitaxel (100 mg/m 2 ) once weekly for 6 weeks followed by 1 week rest. Patients with gastric cancer received recurrent docetaxel (60 mg/m 2 ) infusions every 3 weeks or recurrent paclitaxel (80 mg/m 2 ) once weekly for 3 weeks followed by 1 week rest. Patients with breast cancer received recurrent paclitaxel (80 mg/m 2 ) once weekly for 3 weeks followed by 1 week rest. When the tumor progression or adverse event (allergy or interstitial pneumonia) was observed in patients, the first taxane was changed to the second one in this study.
Evaluation and statistical analysis
We assigned patients to one of the three groups. Patients in the first group exhibited only a partial response (PR) to the first taxane treatment (PR group; defined as a ≧30% reduction in the diameter of measurable lesions on computed tomography [CT] ) and subsequently became refractory to the treatment. The second group comprised patients whose response to the first taxane treatment was stable disease (SD; SD group; defined as a <30% reduction and a <20% increase in the diameter of measurable lesions as shown on CT). Finally, the third group comprised patients whose response was disease progression (progression disease [PD] group; defined as a ≧20% increase in the diameter of measurable lesions as shown on CT). Notably, the responses were assessed using the Response Criteria in Solid Tumor, version 1.0. 13 We combined the rate of the complete response (CR; or all signs of cancer disappearing with the taxane treatment) and PR and used as the response rate. In addition, the rates of CR, PR, and SD were combined and used as the disease control rate. Then, all toxicities were reviewed from the medical records and evaluated as per the Common Terminology Criteria for Adverse Events, version 4.0.
14 Furthermore, we performed a univariate analysis, multivariate analysis, and Pearson's chi-squared test using JMP 11, version 13.1 (SAS Institute Inc., Cary, NC, USA). We considered P=0.05 as the statistical significance.
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Results

Patients' characteristics
We identified 31 patients who were successively treated with paclitaxel or docetaxel during their treatment. Table 1 summarizes the patients' characteristics. The primary cancer sites were the esophagus (n=14), stomach (n=12), head and neck (n=4), and breast (n=1). While 19 patients were first treated with paclitaxel, followed by docetaxel, 12 were first treated with docetaxel, followed by paclitaxel. In addition, 28 patients received, at least, one anticancer drug other than the taxanes.
Predictive factors for the efficacy of the second taxane treatment
We conducted univariate and multivariate analyses to determine the predictive factors for the efficacy of the second taxane treatment in patients who became refractory to the first taxane and assess a correlation between both ( Table 2) . We established statistically significant correlations between the tumor shrinkage with the first taxane treatment and the tumor shrinkage with the second taxane treatment (P=0.0061 and P=0.0056, respectively). In addition, we analyzed the other three factors, the time interval between the first taxane treatment and the second, histology, and the order of the taxane treatment that did not markedly correlate with the efficacy of the second taxane treatment. 
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Efficacy of the second taxane treatment
Next, we assessed the efficacy of the second taxane treatment in patients who were resistant to the first. We assigned patients to either the PR group (n=12), SD group (n=5), or PD group (n=14) and assessed the differences in the response rates in each group (Table 3) . Response rates to the second taxane treatment in the PR, SD, and PD groups were 33.3%, 0%, and 0%, respectively (Table 4 ). In addition, disease control rates with the second taxane treatment in the PR, SD, and PD groups were 58.3%, 40.0%, and 14.3%, respectively (Table 4 ). All patients who exhibited tumor shrinkage with the second taxane treatment were included in the PR group ( Figure 1) . A large proportion of patients in the SD and PD groups experienced the disease progression with the second taxane treatment. The median progression-free survival time of the PR, SD, and PD groups was 124 days (95% CI: 72-194 days), 77 days (95% CI: 35-86 days), and 55.5 days (95% CI: 36-95 days), respectively ( Figure 2 ). Based on the results of the log-rank test, the progression-free survival rate of the PR group was significantly higher than that of the SD and PD groups (the PR group vs the SD group, P=0.0456; the PR group vs the PD group, P=0.0087).
Toxicities Table 5 presents the toxicities caused by the second taxane treatment in the PR, SD, and PD groups. We observed severe hematological toxicities in approximately 20% of the patients in each group. In addition, we observed a few patients with nonhematological toxicities (anorexia and fatigue) in each group. However, no significant differences were observed in the percentages of both hematological and nonhematological toxicities among the three groups.
Discussion
In this study, we used univariate and multivariate analyses to determine the predictive factors for the efficacy of the second taxane treatment in patients refractory to the first treatment. These findings suggest that tumor shrinkage by the second taxane treatment is anticipated in patients who exhibited tumor shrinkage with the first treatment, even when these tumors become refractory to the first treatment.
In this study, we categorized patients into one of the three groups (PR, SD, and PD groups; Table 3 ) and analyzed the response rate of each group to the second taxane treatment. The PR group comprised all patients who exhibited tumor shrinkage with the second taxane treatment (Table 4 and Figure 1 ). In the PR group, the progression-free survival rate with the second taxane treatment was considerably longer than that of patients in the SD and PD groups (Figure 2 ). Prior studies reported that response rates to the second taxane treatment in patients with gastric cancer, esophageal cancer, and breast cancer resistant to the first taxane treatment were 12.8%, 20.0%, and 19.5%, respectively. [9] [10] [11] In this study, the response rate to the second taxane treatment in the PR group (33.3%) was higher than that reported previously, suggesting that the determined predictive factor could be applied to 
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imai et al patients in whom tumors were highly expected to respond to the second taxane treatment when tumors were refractory to the first taxane treatment. Furthermore, no patient exhibited tumor shrinkage with the second taxane treatment in either the SD or the PD group, suggesting that the second taxane treatment comprised only a weak ability to control tumor growth in patients who did not exhibit tumor shrinkage with the first taxane treatment.
Consistent with previous studies, the response rate to the second taxane (paclitaxel) treatment in patients with breast cancer who exhibited tumor shrinkage with the first (docetaxel) treatment (24.1%) was higher than the response rate in patients who did not exhibit tumor shrinkage with the first (docetaxel) treatment (8.3%). 11 These results supported the idea that tumor shrinkage with the first taxane treatment could be used as a predictive factor for a response to the second treatment.
Reportedly, a variation in an isotype of β-tubulin in cancer cells seemingly associated with the response to taxanes. 15, 16 In these studies, the βIII isotype of tubulin exhibited less Table 2 Univariate and multivariate analyses for the relationship between the tumor response by the first taxane treatment and the tumor response by the second taxane treatment in patients who were resistant to the first taxane treatment stability than other isotypes of tubulin. As taxanes affect the stabilized β-tubulin, 16 the overexpression of βIII-tubulin could be related to a poor response to paclitaxel or docetaxel. In addition, the overexpression of βIII-tubulin was reported to be a substantial cause of resistance to taxanes. 15, 16 Perhaps, several patients in this study did not exhibit tumor shrinkage by either paclitaxel or docetaxel because of this βIII-tubulin mechanism. 15, 16 However, why all four patients who exhibited tumor shrinkage with the second taxane treatment were included in the PR group in this study cannot be explained by such a mechanism. Reportedly, cancer cells treated with taxanes expressed the multidrug resistance (MDR1) gene, 17 encoded the plasma membrane P-glycoprotein (ABCB1), which acted as adenosine triphosphate (ATP)-dependent efflux pump for taxanes. This mechanism leads cancer cells to become refractory to taxanes. 17 In the four patients who exhibited tumor shrinkage with the second taxane treatment in this study, ABCB1 in their cancer cells might not have had the ability to excrete the second taxane. If this hypothesis is correct, it would clarify why all the patients who exhibited 
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Predictive factors for taxane treatment in advanced cancer tumor shrinkage with the second taxane treatment were included in the PR group. However, the precise mechanism remains unclear to date. Thus, further studies on crossresistance between the two taxanes are warranted.
Cabazitaxel is a next-generation taxane that has been approved for metastatic castration-resistant prostate cancer.
18 Table 3 Characteristics of patients in the first taxane PR, SD, and PD groups 
Note: P-value was analyzed using the Pearson's chi-squared test. Abbreviations: CDDP, cisplatin; DTX, docetaxel; 5-FU, 5-fluorouracil; PD, progression disease; PR, partial response; PTX, paclitaxel; SD, stable disease; S-1, Tegafur/ Gimeracil/Oteracil.
A previous Phase III study reported that the median overall survival time by a cabazitaxel-containing regimen in patients who had progressed during or after a docetaxel-based regimen was 15.1 months, which was markedly longer than that with the control arm (12.7 months). 19 Thus, cabazitaxel seems to be modestly effective in patients refractory to docetaxel Of note, it is intriguing to assess whether cabazitaxel therapy has higher efficacy in patients who exhibited tumor shrinkage by docetaxel therapy than in patients who did not exhibit tumor shrinkage by docetaxel therapy. This study has some limitations. First, this study enrolled a low number of eligible patients. Second, the study was retrospective in nature. Third, the fact that we did not enroll patients with lung and ovarian cancer, for whom taxane is an approved treatment, is another major limitation. Fourth, the basal condition varied among the three groups. Although the tumor volume of those in the PR group was decreased by the first taxane treatment, the tumor volume of those in the SD and PD groups was not decreased by the first taxane treatment. In addition, tumors in patients in the SD and PD groups might exhibit a low reactivity to taxanes compared with patients in the first taxane PR group. However, all tumors in the PR and SD groups became refractory to the first taxane treatment before the second taxane treatment was started. Thus, the tumors in all three groups were growing when the second taxane treatment was initiated. Hence, it should be emphasized that tumor shrinkages were observed only in patients in the first taxane PR group.
Conclusion
The second taxane treatment after a PR to the first is highly recommended. Nevertheless, further studies are warranted to investigate the efficacy of the second taxane treatment in patients who are refractory to their first taxane treatment.
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